- Location
Qiagen
"-
Qiagen Announces Commercial Launch in India of Its CareHPV Test
Feb 28, 2014Qiagen has announced the commercial launch in India of its careHPV test, the only molecular diagnostic for high-risk human papillomavirus (HPV) designed to screen women in settings with limited healthcare infrastructure, such as areas ...
Tags: CareHPV Test, Qiagen
-
BD Launches The Paxgene Blood DNA Tube in Europe
Feb 8, 2014BD Launches the PAXgene® Blood DNA Tube in Europe BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the commercial availability of the CE-marked PAXgene® Blood DNA Tube in Europe. The ...
Tags: BD, DNA, PAXgene, PreAnalytiX GmbH
-
BD Declares Commercial Availability of Its Paxgene Blood DNA Tube
Feb 7, 2014Becton, Dickinson and Company (BD) has announced the commercial availability of its PAXgene blood DNA tube, a blood collection tube designed specifically for IVD genomic DNA testing, in Europe. Initial target customers for the CE-marked ...
Tags: BD, Qiagen, dna, PreAnalytiX
-
LabCorp Has Announced The Nationwide Availability of Qiagen's Therascreen KRAS RGQ PCR Kit
Oct 29, 2013Laboratory Corporation of America Holdings (LabCorp) has announced the nationwide availability of QIAGEN’s therascreen KRAS RGQ PCR kit, a new US Food and Drug Administration (FDA) approved companion diagnostic for certain colorectal ...
Tags: Labcorp, Colorectal Cancer
-
FDA Has Cleared Gilotrif as a New Medication for Patients with Late Stage NSCLC
Jul 16, 2013The US Food and Drug Administration (FDA) has cleared Boehringer Ingelheim's tyrosine kinase inhibitor Gilotrif (afatinib) as a new medication for patients with late stage (metastatic) non-small cell lung cancer (NSCLC). The approval also ...
Tags: FDA, Lung Cancer Therapy, Medicine
-
The First Chinese Translational Medicine Center Has Been Put Into Operation
May 30, 2013The first Chinese R&D center focusing on translational medicine QIAGEN (Suzhou) Translational Medicine Center has been put into operation as a JV between German QIAGEN and SIP Biotech Development Co., Ltd. (BioBAY). Translational medicine ...
-
Sygnis Pharma Has Entered Into a Licence Agreement for The Distribution
May 21, 2013Spanish-German biotech company Sygnis Pharma has entered into a licence agreement for the distribution of a new amplification buffer with QIAGEN, a sample and assay technologies provider. This is the second agreement with QIAGEN within ...
Tags: Sygnis Pharma, Buffer to Qiagen
-
Qiagen Has Won The US FDA Approval for Its New Molecular Companion Diagnostic Product
Dec 7, 2012Qiagen has won the US Food and Drug Administration (FDA) approval for its new molecular companion diagnostic product, therascreen KRAS RGQ PCR test kit, to provide guidance on the use of Erbitux for approximately 110,000 US patients with ...
Tags: Qiagen, FDA, molecular companion diagnostic product, test kit
-
Aoac Validation Approvals Qiagen's Mericon Salmonella Spp. Kit
Dec 4, 2012Dutch biotechnology company Qiagen has announced that its mericon Salmonella spp. kit in combination with the QIAsymphony RGQ automation platform has received validation from the AOAC Research Institute. AOAC Research Institute is an ...
Tags: mericon Salmonella spp.kit, validation from the AOAC Research Institute
-
Sygnis Pharma Will Join Forces with X-Pol Biotech to Secure Sustainable Business Model
Nov 30, 2012Sygnis Pharma will join forces with X-Pol Biotech to secure sustainable business model. The company believes that the changes are essential after the termination of clinical development activities in December 2011. Sygnis' new business ...
-
BMY and LLY Receive an Approval From Us FDA to Expand The Use of Erbitux
Jul 9, 2012Bristol-Myers Squibb (BMY) and Eli Lilly (LLY) have received an approval from US Food and Drug Administration (FDA) to expand the use of Erbitux in combination with the chemotherapy regimen Folfiri as an initial treatment of patients with ...
Tags: FDA approval, Erbitux, KRAS mutation-negative colorectal cancer
